ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,132.48
-0.43%
Dow Jones
40,358.09
-0.14%
Gold vs US Dollar
2,412.305
0.15%
Brent Oil
80.925
0.19%
Bitcoin
66,429.93
0.77%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Ose Immunotherapeutics Sa (0RAD) Share Price

0RAD Ose Immunotherapeutics Sa

4.12
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Ose Immunotherapeutics Sa LSE:0RAD London Stock Exchange Ordinary Share FR0012127173 ORPHAN SYNERGY EUROPE IMMUNOTHERAPEUTICS
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.00 0.00 4.12 0.00 0.00 0.00 0.00  14 00:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Coml Physical, Biologcl Resh 2.23M -23M -1.1759 -5.71 80.6M
 Type  Size  Price  Time  Units 
  14 6.67 08:20:12 EUR
 
Recent News
DateTimeSource
HeadlineMore 0RAD News
24/07/202407:55UKREGOSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis
24/07/202407:55UKREGOSE Immunotherapeutics annonce des résultats positifs d'efficacité de Lusvertikimab dans l'essai clinique de phase 2 pour le traitement de la rectocolite hémorragique
03/07/202417:00GLOBEOSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer
03/07/202417:00GLOBEBoehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
02/07/202417:00GLOBEInformations relatives au nombre total de droits de vote et d’actions composant le capital
01/07/202406:30GLOBEOSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
01/07/202406:30GLOBEOSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ 
Period
Draw mode
Data Downloads for 0RAD

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)
Technical Analysis for Ose Immunotherapeutics Sa
Get quick technical analysis for Ose Immunotherapeutics Sa.
Price Indicators
Evaluate in real-time the trend for this stock with base on twelve different studies.
Candlesticks
Verify the trend for the closing and opening times for this stock or defined reversal patterns.
Support & Resistance
Automatically plot the main lines for support and resistance for this tock highlighting the main levels.


Loading Follow Feed...

Latest Ose Immunotherapeutics Sa Articles